Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.
BMC Endocr DisordSep 15, 2026 (epub)
Mohamed Gamal Hegaz, Mohammad Yassin Al Aboud, Abanoub I I Kamel et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of orforglipron 12 mg versus 36 mg in 3459 obese adults, with or without diabetes. The 36 mg dose resulted in significantly greater reductions in percentage body weight, absolute body weight, BMI, HbA1c, waist circumference, triglycerides, and systolic blood pressure (all p < 0.00001).
Key findings
- Orforglipron 36 mg led to a greater percentage body weight reduction compared to 12 mg (p < 0.00001).
- The 36 mg dose resulted in a significant decrease in HbA1c levels (p < 0.00001).
- Systolic blood pressure was significantly reduced with the 36 mg dose (P = 0.002).
- Adverse events were comparable between the two doses, with no significant differences in gastrointestinal events.
Why it matters
Understanding the comparative efficacy of different doses of orforglipron can guide clinicians in optimizing treatment for obesity and its associated metabolic disorders, potentially improving patient outcomes.